Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,906 Shares of Company Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Brophy sold 1,906 shares of Natera stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $425.55, for a total transaction of $811,098.30. Following the completion of the transaction, the chief financial officer directly owned 46,574 shares in the company, valued at approximately $19,819,565.70. This represents a 3.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The stock was sold at an average price of $426.34, for a total transaction of $510,755.32.
• On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The stock was sold at an average price of $406.00, for a total transaction of $317,086.00.
• On Tuesday, August 4th, Michael Brophy sold 478 shares of Natera stock. The shares were sold at an average price of $274.22, for a total transaction of $131,077.16.
• On Monday, August 3rd, Michael Brophy sold 317 shares of Natera stock. The shares were sold at an average price of $267.99, for a total transaction of $84,952.83.

Natera Stock Performance

NTRA traded down $21.70 during trading on Friday, hitting $414.30. The stock had a trading volume of 2,431,930 shares, compared to its average volume of 1,559,061. Natera, Inc. has a 12 month low of $181.00 and a 12 month high of $437.41. The company has a 50 day simple moving average of $377.06 and a 200-day simple moving average of $266.44.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.74) earnings per share. As a group, analysts expect that Natera, Inc. will post -1.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent analyst reports. Roth Capital started coverage on Natera in a research note on Thursday, October 22nd. They set a “buy” rating and a $475.00 target price for the company. Rothschild & Co Redburn initiated coverage on Natera in a research report on Tuesday, September 8th. They issued a “buy” rating and a $385.00 price target on the stock. Citigroup upped their price target on Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. Wells Fargo & Company increased their price objective on Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Finally, Guggenheim raised their price objective on shares of Natera from $360.00 to $475.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average target price of $394.31.

Institutional Investors Weigh In On Natera

Several hedge funds have recently made changes to their positions in NTRA. Provenance Wealth Advisors LLC bought a new stake in shares of Natera in the 3rd quarter worth approximately $89,000. Factory Mutual Insurance Co. bought a new stake in shares of Natera during the third quarter valued at approximately $491,000. Aware Super Pty Ltd as trustee of Aware Super acquired a new position in shares of Natera in the third quarter valued at $6,620,000. Greenleaf Trust bought a new position in Natera in the third quarter worth $240,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Natera in the third quarter worth $7,545,000. Institutional investors own 99.90% of the company’s stock.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera’s stock momentum remains strong after reaching a new 52-week high of approximately $436, reflecting continued investor enthusiasm for its oncology testing business and Signatera growth prospects. Natera reaches a fresh 52-week high
• Positive Sentiment: Recent ESMO oncology data, including 25 company presentations and additional Signatera evidence, could support broader clinical adoption and future revenue growth. Natera presents 25 ESMO abstracts
• Neutral Sentiment: Natera is scheduled to report third-quarter 2026 results after the market closes on November 5. The report will provide a near-term catalyst focused on Signatera testing volumes, pricing, reimbursement and profitability. Natera third-quarter results announcement
• Negative Sentiment: Several insiders sold shares this week, including the CEO, CFO and other executives. The transactions totaled roughly 11,500 shares, but each sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making the signal less concerning than discretionary selling. Natera insider selling
• Negative Sentiment: Zacks warned that Natera may report another quarterly loss and does not currently show the usual combination of positive estimate revisions and earnings momentum associated with a likely beat. With the stock trading well above its long-term moving averages and some valuation analyses estimating substantial downside to fair value, investors may be taking profits ahead of earnings. Natera earnings outlook

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.